Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU

THOUSAND OAKS, Calif. and BRUSSELS, June 27, 2019 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for Human Use (C... Biopharmaceuticals, Regulatory Amgen, UCB , EVENITY, romosozumab, osteoporosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news